Compassionate Use of Vorinostat (MK0683) for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma.

Trial Profile

Compassionate Use of Vorinostat (MK0683) for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 May 2017

At a glance

  • Drugs Vorinostat (Primary)
  • Indications Cutaneous T cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 03 Mar 2012 Planned number of patients changed from 65 to 100 as reported by European Clinical Trials Database.
    • 21 Feb 2012 Planned end date changed from 1 May 2011 to 1 Mar 2012 as reported by ClinicalTrials.gov.
    • 13 Jan 2011 Planned End Date changed from 1 Aug 2010 to 1 Mar 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top